Basal anti-cyclic citrullinated peptide (anti-CCP) antibody levels and a decrease in anti-CCP titres are associated with clinical response to adalimumab in rheumatoid arthritis

To investigate the effect of adalimumab treatment on anti-cyclic citrullinated peptide antibodies (anti-CCP) in patients with rheumatoid arthritis (RA). 70 RA patients who failed treatment with disease modifying antirheumatic drugs (DMARDs) received 40 mg adalimumab subcutaneously every other week d...

Full description

Saved in:
Bibliographic Details
Published in:Clinical and experimental rheumatology 2008-11, Vol.26 (6), p.1067-1073
Main Authors: CUCHACOVICH, M, CATALAN, D, WAINSTEIN, E, GATICA, H, SOTO, L, ARAVENA, O, PESCE, B, SABUGO, F, AGUILLON, J. C
Format: Article
Language:English
Subjects:
Adalimumab
Adult
Antibodies, Monoclonal - administration & dosage
Antibodies, Monoclonal, Humanized
Antirheumatic Agents - administration & dosage
Arthritis, Rheumatoid - drug therapy
Arthritis, Rheumatoid - immunology
Autoantibodies - blood
Biological and medical sciences
Biomarkers - blood
Diseases of the osteoarticular system
Drug Monitoring - methods
Female
Humans
Immunomodulators
Inflammatory joint diseases
Male
Medical sciences
Middle Aged
Peptides, Cyclic - immunology
Pharmacology. Drug treatments
Predictive Value of Tests
Rheumatoid Factor - blood
Treatment Outcome
Tumor Necrosis Factor-alpha - antagonists & inhibitors
Tumor Necrosis Factor-alpha - immunology
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:To investigate the effect of adalimumab treatment on anti-cyclic citrullinated peptide antibodies (anti-CCP) in patients with rheumatoid arthritis (RA). 70 RA patients who failed treatment with disease modifying antirheumatic drugs (DMARDs) received 40 mg adalimumab subcutaneously every other week during 24 weeks. Serum samples were collected at baseline and at weeks 8, 16 and 24 before the corresponding adalimumab dose. The serum anti-CCP levels were tested by enzyme linked immunosorbent assay. At baseline, 52 of the 70 patients (74.3%) were positive for anti-CCP antibodies. 60 % of the anti CCP positive patients and 44.4% of the anti CCP negative patients were ACR 20 responders at week 24 (p
ISSN:0392-856X
1593-098X